Appointment of Director of Project Planning

RNS Number : 6005F

Advanced Oncotherapy PLC

28 April 2014

 

28 April 2014                                                                                                                                                   

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Appointment of Director of Project Planning

Advanced Oncotherapy (AIM: AVO), the developer of innovative medical technology for cancer treatment, announces the appointment of Eric Ferret to project manage the design and construction of the commercial installations of the Company's proprietary technology, the Linac Image Guided Hadron Therapy (LIGHT) system for generating a proton beam for therapeutic use.

Eric will be responsible for the design, construction and workflow interface with new and existing customers to develop and deliver viable solutions for proton radiation therapy based on the healthcare systems clinical requirements. This expands Advanced Oncotherapy's expertise in partnering with hospital teams to secure project funding and if necessary to deliver the LIGHT facility from design through to construction.

Eric has over 20 years of professional experience as an architectural programmer, planner and project manager in building next generation healthcare facilities. His most recent involvement has been in planning four proton beam therapy centres across the US.

During his career he has been involved as a project manager in building 11 specialist medical facilities, including the four proton therapy centres mentioned above, 17 academic facilities, 21 corporate facilities, mainly for pharmaceutical companies and 7 hospitals. This impressive track record makes him particularly suited to head up the project management team as Advanced Oncotherapy moves towards the delivery phase of its affordable and compact system to deliver radiation therapy with protons.

Karen Bullivant, Director of marketing and new business commented: "Eric brings to our Executive team the expertise and experience to help our customers progress their vision with efficiency and speed on budget and on schedule."  

Michael Sinclair, CEO of Advanced Oncotherapy commented: "Following the recent successful fund raise of £6m, the appointment of Eric completes the resources we need to manufacture market and install LIGHT systems in a more cost effective and customer focussed manner.  At every level, from nuclear physics to engineering, software development and now facility development, we have experts to guide us on the successful implementation and commercialisation of our novel technology."

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Michael Sinclair, CEO	Tel: [phone]
Westhouse Securities (Nomad & Joint Broker)	Tel: [phone]
Antonio Bossi / David Coaten
Peterhouse Corporate Finance (Joint Broker)	Tel: [phone]
Jon Levinson / Lucy Williams
Walbrook PR (Financial PR & IR)
Anna Dunphy/Mike Wort	Tel: [phone] or [e-mail]

About Advanced Oncotherapy

Vision:

To advance patients' clinical treatments and improve their everyday lives by harnessing innovative science and focusing it to develop the most effective and affordable cancer treatments.

Mission:

To facilitate the wider use of radiation with protons for treating all forms of cancerous tumours by commercialising novel technologies inspired by CERN and the Large Hadron Collider.

Key corporate messages:

AVO's team based at CERN near Geneva focuses on the development of a proprietary proton system called Linac Image Guided Hadron Technology (LIGHT). This LIGHT system accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

AVO is a provider of proton radiotherapy that harnesses the best in modern technology.  As a result, the Company will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology which is proven to bring better health outcomes and lower treatment related side effects.

AVO continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships the Company will remain the prime provider of innovative and cost-effective equipment for proton radiation. This will allow healthcare suppliers to access more cost effective and more efficient ways to treat the increasing number of cancer patients who expect lower short term and long term side effects of their cancer care. 

AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.

Through its shareholding and collaboration with Advanced Proton Solutions (APS), AVO can offer a complete turnkey solution to the design installation and operation of its LIGHT proton system for healthcare providers. This is attractive to potential purchasers and has led to its involvement in the development of the first comprehensive proton beam therapy centre in London to treat both NHS and private patients. 

For more information, please visit http://www.avoplc.com

 

END

 

 

MSCSEUFMMFLSEFL